Abstract
Purpose
Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small. Our goal was to develop a tool for identification of women with limited treatment benefit.
Methods
Regression analyses were applied to women treated by placebo in CCTG MA.17R trial (NCT00754845) to identify important prognostic factors associated with distant recurrence and develop a nomogram for predicting 5-year likelihood of distant recurrence, which was internally validated using bootstrap resampling method. Differential treatment effects between risk categories derived from the nomogram were evaluated among all women enrolled through interaction test between treatment and risk category.
Results
A total of 1735 women were included and the final model from 866 women treated by placebo identified the following three factors associate with distant recurrence: tumor size, nodal status, and presence of cardiovascular disease. The nomogram derived from the final model exhibited good discrimination power with a bootstrap-corrected concordance index of 0.71 and, importantly, identified 64% of low risk patients in whom extended treatment has limited benefit. Interaction between treatment and risk category derived from the nomogram was significant (p = 0.04).
Conclusion
A nomogram with good performance may be used to accurately predict distant recurrence risk and also benefits with extended treatment after 5 years of aromatase inhibitors. Future independent validation of the proposed nomogram is warranted.
Trial registration number
NCT00754845
Similar content being viewed by others
Data availability
Data can be requested by writing to the corresponding author.
References
Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802
Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141
Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108
Ingle JN, Schaid DJ, Goss PE et al (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674–4682
O’Leary CG, Ellis H, Higgins M (2016) Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. Curr Opin Oncol 28:455–460
Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209–219
Sestak I, Dowsett M, Zabaglo L et al (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105:1504–1511
Sestak I, Buus R, Cuzick J et al (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer. a secondary analysis of a randomised trial. JAMA Oncol 4:545–553
Dowsett M, Sestak I, Regan MM et al (2018) Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol 36:1941–1948
Moreau-Bachelard C, Campion L, Robert M et al (2020) Development of a prognostic tool to guide the decision to extend adjuvant aromatase inhibitors for up to ten years in postmenopausal early breast cancer patients. Cancers 12:3725. https://doi.org/10.3390/cancers12123725
Satagopan JM, Ben-Porat L, Berwick M et al (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229–1235
Austin PC, Lee DS, Fine JP (2016) Introduction to the analysis of survival data in the presence of competing risks. Circulation 133:601–609
Ethier JL, Anderson GM, Austin PC et al (2021) Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: a secondary analysis of MA.27, MA.17 and MA.17R. Eur J Cancer 149:117–127
Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Amer Stat Assoc 94:496–509
Wolbers M, Koller M, Witteman J et al (2009) Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 20:555–561
Gray RJ (2019) cmprsk: subdistribution analysis of competing risks. R package version 2.2-9. http://CRAN.R-project.org/package=cmprsk. Accessed 19 Nov 2021
Harrell Jr FE (2019) rms: regression modeling strategies. R package version 5.1-3.1. https://CRAN.R-project.org/package=rms. Accessed 19 Nov 2021
Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187
Mehta LS, Watson KE, Barac A (2018) Cardiovascular disease and breast cancer: where these entities intersect-A scientific statement from the American Heart Association. Circulation 137:e30–e66
McPherson K, Steel CM, Dixon JM (2000) Breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624–628
West HJ, Jin JO (2015) Performance status in patients with cancer. JAMA Oncol 1:998
Foldi J, O’Meara T, Marczyk M et al (2019) Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: clinical versus molecular tools. J Clin Oncol 37:1365–1369
Sgroi DC, Carney E, Zarrella E et al (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105:1036–1042
Filipits M, Dubsky P, Rudas M et al (2019) Prediction of distant recurrence using endopredict among women with ER(+), HER2(-) node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res 25:3865–3872
Mamounas EP, Bandos H, Rastogi P et al (2021) Breast cancer index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. J Clin Onco 39:501
Rastogi P, Bandos H, Lucas PC et al (2021) Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG oncology/NSABP B-42 trial. J Clin Onco 39:502
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Li, Y., Zheng, X., Tu, D. et al. Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. Breast Cancer Res Treat 191, 523–533 (2022). https://doi.org/10.1007/s10549-021-06448-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-021-06448-5